in community-dwelling older adults: results of a randomized controlled trial.
In South Korea, where the National Health Insurance provides universal coverage, the Health Insurance Review & Assessment Service (HIRA) oversees claims reviews, quality assessment, and benefits and coverage standards. Since 2001, HIRA has used claims data to assess the appropriateness of care based on various quality indicators, including the antibiotic prescription rate for URTIs, 3 and has used them for monitoring and giving feedback to physicians. Because it is a prerequisite that the public perceive low antibiotic prescription rates as good quality of care, starting in February 2006, HIRA began warning the public of the potential harms of antibiotic overuse through television and radio campaigns. In addition, HIRA has disclosed physicians' antibiotic prescription rates to the general public via its website. We evaluated the effect of such public disclosure using nationally representative data.
Methods | From the National Health Insurance claims data, a random sample of 3% of the adult population was selected (1 162 354 persons who were 20 years or older on December 31, 2002). The claims data of medical services, which include all prescriptions written from January 1, 2003, through December 31, 2010, were used.
From these data, we defined the cases of URTI based on the International Classification of Diseases, Tenth Revision (ICD-10) codes J00 through J06, and the antibiotics according to their Anatomical Therapeutic Chemical classification (J01 category).
To perform segmented regression, we totaled the visits each month and calculated the rate of antibiotic use. We performed segmented linear regression to compare the trend of antibiotic use before and after February 1, 2006. We analyzed the trend using the autoregressive integrated moving average model, which included the seasonal effect. We also compared the rates by intervention at 3 hospital levels: primary clinic, secondary care hospital, and tertiary care hospital. Analyses were conducted using STATA, version 13.1 (StataCorp).
Results | From the predefined cohort, 938 118 persons with URTI (80.7%) had visited a clinic at least once between January 1, 2003, and December 31, 2010. The number of visits was 11 665 529, and 95.7% of the visits were to primary clinics.
The rates of antibiotic prescriptions before and after public disclosure were 58.8% and 53.0%, respectively, and the decrease in rates by intervention were consistent regardless of the hospital level (Table) .
Segmented linear regression showed that antibiotic prescription rates abruptly decreased by February 2006, and differences between actual rates and predicted rates persisted until the end of the follow-up period. Autoregressive integrated moving average models showed that all actual rates after the intervention were below the predicted values, and most rates were observed below the lower limits of the 95% CIs (Figure) .
Discussion | Our data show that public disclosure was effective in lowering antibiotic use for URTIs. Based on the findings in a previous study 4 on the effect of publicly disclosing quality improvement in other clinical areas, 2 primary mechanisms can be suggested: selection of high-quality providers by patients and provider response to report cards. A survey 5 in 2007 found that 21.5% of health consumers were aware of the disclosure of antibiotic prescription rates and 40.3% of them had changed their health care provider. The survey also found that 95.0% of physicians were aware, and the abrupt change might be explained by observer effect.
6
Our study should be interpreted within the context of South Korea's medical care, in which medical services are provided mostly by private providers who might be motivated to maintain a good reputation for economic reasons. In addition, the preexisting National Health Insurance database for fee-for-service reimbursement makes individual medical institutions' antibiotic prescription rate easily available and implementation of the program affordable.
A substantial proportion of computed tomographic pulmonary angiography (CTPA) results are degraded by patientrelated and technical factors, yielding a limited negative interpretation, which qualifies the definitive exclusion of pulmonary embolism. This leads to diagnostic uncertainty and may affect patient management. A multicenter randomized clinical trial of CTPA vs ventilation-perfusion scintigraphy considered CTPA results negative if no pulmonary embolism was demonstrated to the lobar level.
1 Investigators have explicitly questioned the clinical relevance of small pulmonary emboli, 2,3 and there is growing concern that pulmonary embolism is overdiagnosed on CTPA.
4,5
We hypothesized that a limited negative CTPA result portends similar clinical outcomes to a definitively negative result; thus, emphasis on examination limitations may, in fact, be detrimental.
Methods | This retrospective cohort study was approved by the institutional review board of the Montefiore Medical Center, which waived written informed consent. Included were all adults with suspected pulmonary embolism who underwent CTPA from July 1, 2011, through June 30, 2012, at the 3 emergency departments or inpatient sites of Montefiore Medical Center, Bronx, New York. We defined a limited negative CTPA result as one that reported no pulmonary embolism but also explicitly stated a limitation or qualification in the report impression. The primary outcome was 90-day venous thromboembolism incidence, a measure of the false-negative rate. Secondary outcomes were additional imaging, initiation of anticoagulation treatment, and bleeding complications.
Results | The study population comprised 2553 patients with mean (SD) age 55 (18) years, 66% women and 85% ethnic minorities. A total of 264 CTPA results (10%) were positive; 1663 (65%) were definitively negative; 569 (22%) were limited negative; and 57 (2%) were nondiagnostic for pulmonary embolism. In all, 25% of negative CTPA results (569 of 2232) were limited negative. Patients with limited negative CTPA results were more similar to patients with definitely negative results than they were to patients with positive results in their baseline characteristics and outcomes ( Table 1) .
The false-negative rate (90-day venous thromboembolism incidence) for patients with a limited negative CTPA re- 
